Received Jan 30, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
received my first Shingrix injection at my local about six or seven years ago/ in October 2025 got my first injection again; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose at his local about 6 or 7 years ago on an unknown date). In OCT-2025, the patient received the 2nd dose of Shingrix. In OCT-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: received my first Shingrix injection at my local about six or seven years ago/ in October 2025 got my first injection again). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 26-JAN-2026 The patient self-reported this case for himself. The patient stated that he had failed to receive the booster dose of Shingrix. He had tried to start the series over again, and in OCT-2025 he had gone to the pharmacy and had received the first injection again. When he returned during this (reporting time) week for his booster dose, the pharmacy had refused to administer it because, according to their records, it appeared that the patient had already received two doses. The pharmacy reportedly informed the patient that the only way to receive another dose would be through a prescription from their physician, and the patient might have had to pay for it out of pocket. The pharmacy also stated that the patient might have been close to being fully protected because the October dose was considered a booster. The batch number was not provided and unable to contact the reporter.